Abstract：
OBJECTIVE: Oral squamous cell carcinoma (OSCC) is among the most malignant cancers in the world and has a high mortality rate. MicroRNAs (miRNAs) have progressively gained attention due to their roles in the pathogenesis and maintenance of various kinds of cancers, including OSCC. In this research, we carried out a scoping review to analyze the role of miRNA and therapeutic response in OSCC and focus on target axes associated with miRNA that inhibit metastasis and cell proliferation in OSCC.
METHODS: This review adhered to a six-stage methodology framework and PRISMA guidelines. Three databases were systematically searched to find eligible articles until July 2024. Two reviewers conducted publication screening and data extraction independently. 54 articles meeting the predefined inclusion criteria were successfully identified. Quality assessment was done using the QUIN checklist specified for dental in vitro studies.
RESULTS: Studies with different designs reported 53 miRNAs that were experimentally validated to act as therapeutic targets in OSCC in vivo and in vitro studies. The study found that 25 miRNAs were up-regulated in OSCC patients and cell lines, while another 25 were down-regulated. Mir-186 was also found to be up- and down-regulated in two different investigations. The study highlights the potential of six microRNAs (miR-32-5p, miR-195-5p, miR-3529-3p, miR-191, miR-146b-5p, and miR-377-3p) as anti-proliferation, migration, and invasion therapeutics for OSCC treatment. Two miRNAs (miR-302b and miR-18a) are identified as anti-metastatic therapeutics, while four miRNAs (miR-617, miR-23a-3p, miR-105, miR-101) are anti-proliferation therapeutics.
CONCLUSIONS: The study recommends that restoring the expression of tumor suppressor miRNAs may be a suitable cancer therapy. Utilizing this technology does present certain difficulties, and resolving them will improve the methods for miRNA transfer to target cells. With more research and the resolution of associated issues, miRNA can be employed as an efficient therapeutic method for OSCC.
METHODS: This review adhered to a six-stage methodology framework and PRISMA guidelines. Three databases were systematically searched to find eligible articles until July 2024. Two reviewers conducted publication screening and data extraction independently. 54 articles meeting the predefined inclusion criteria were successfully identified. Quality assessment was done using the QUIN checklist specified for dental in vitro studies.
RESULTS: Studies with different designs reported 53 miRNAs that were experimentally validated to act as therapeutic targets in OSCC in vivo and in vitro studies. The study found that 25 miRNAs were up-regulated in OSCC patients and cell lines, while another 25 were down-regulated. Mir-186 was also found to be up- and down-regulated in two different investigations. The study highlights the potential of six microRNAs (miR-32-5p, miR-195-5p, miR-3529-3p, miR-191, miR-146b-5p, and miR-377-3p) as anti-proliferation, migration, and invasion therapeutics for OSCC treatment. Two miRNAs (miR-302b and miR-18a) are identified as anti-metastatic therapeutics, while four miRNAs (miR-617, miR-23a-3p, miR-105, miR-101) are anti-proliferation therapeutics.
CONCLUSIONS: The study recommends that restoring the expression of tumor suppressor miRNAs may be a suitable cancer therapy. Utilizing this technology does present certain difficulties, and resolving them will improve the methods for miRNA transfer to target cells. With more research and the resolution of associated issues, miRNA can be employed as an efficient therapeutic method for OSCC.
摘要：
目的：口腔鳞状细胞癌（OSCC）是世界上最恶性的癌症之一，死亡率很高。MicroRNAs(miRNAs)由于其在各种癌症的发病机制和维持中的作用而逐渐受到关注。包括OSCC。在这项研究中,我们进行了范围审查,以分析miRNA在OSCC中的作用和治疗反应,并关注与抑制OSCC转移和细胞增殖的miRNA相关的靶轴.
方法：本综述遵循六阶段方法框架和PRISMA指南。在2024年7月之前，系统搜索了三个数据库，以找到合格的文章。两名审稿人独立进行出版物筛选和数据提取。成功确定了54篇符合预定义纳入标准的文章。使用为牙科体外研究指定的QUIN检查表进行质量评估。
结果：具有不同设计的研究报告了53个miRNA，这些miRNA在体内和体外研究中被实验验证为OSCC的治疗靶标。研究发现，25个miRNAs在OSCC患者和细胞系中上调，另有25人被下调。在两项不同的调查中，还发现了Mir-186的上调和下调。该研究强调了六种microRNA（miR-32-5p，miR-195-5p,miR-3529-3p,miR-191,miR-146b-5p,和miR-377-3p）作为抗增殖，迁移,以及用于OSCC治疗的侵袭疗法。两种miRNA（miR-302b和miR-18a）被鉴定为抗转移治疗剂，而四个miRNA(miR-617，miR-23a-3p，miR-105，miR-101）是抗增殖治疗剂。
结论：该研究建议恢复肿瘤抑制miRNA的表达可能是一种合适的癌症治疗方法。利用这项技术确实存在一定的困难，和解决它们将改善miRNA转移到靶细胞的方法。随着更多的研究和相关问题的解决，miRNA可用作OSCC的有效治疗方法。
方法：本综述遵循六阶段方法框架和PRISMA指南。在2024年7月之前，系统搜索了三个数据库，以找到合格的文章。两名审稿人独立进行出版物筛选和数据提取。成功确定了54篇符合预定义纳入标准的文章。使用为牙科体外研究指定的QUIN检查表进行质量评估。
结果：具有不同设计的研究报告了53个miRNA，这些miRNA在体内和体外研究中被实验验证为OSCC的治疗靶标。研究发现，25个miRNAs在OSCC患者和细胞系中上调，另有25人被下调。在两项不同的调查中，还发现了Mir-186的上调和下调。该研究强调了六种microRNA（miR-32-5p，miR-195-5p,miR-3529-3p,miR-191,miR-146b-5p,和miR-377-3p）作为抗增殖，迁移,以及用于OSCC治疗的侵袭疗法。两种miRNA（miR-302b和miR-18a）被鉴定为抗转移治疗剂，而四个miRNA(miR-617，miR-23a-3p，miR-105，miR-101）是抗增殖治疗剂。
结论：该研究建议恢复肿瘤抑制miRNA的表达可能是一种合适的癌症治疗方法。利用这项技术确实存在一定的困难，和解决它们将改善miRNA转移到靶细胞的方法。随着更多的研究和相关问题的解决，miRNA可用作OSCC的有效治疗方法。
